B4GALT5 inhibits CD8⁺ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC.

ABSTRACT:

Background

Immune evasion is a crucial event in the progression of pancreatic ductal adenocarcinoma (PDAC). The identification of new immunotherapeutic targets may provide a promising platform for advancing PDAC treatment. This study aims to investigate the role of beta-1,4-galactosyltransferase-5 (B4GALT5) in immune evasion by pancreatic cancer cells and evaluate its potential as an immunotherapeutic target.

Methods

We conducted a comprehensive analysis using RNA sequencing data and tissue microarrays from patients with PDAC to investigate the association between B4GALT5 expression and patient prognosis. Using animal models, we further explored the impact of B4GALT5 on the quantity and activity of tumor-infiltrating CD8⁺ T cells. RNA sequencing and co-immunopreci

SUBMITTER: Xing X 

PROVIDER: S-EPMC12049881 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature